350 rub
Journal №8 for 2013 г.
Article in number:
Significance of determination of enzyme tyrosinhydroxilase in pathogenesis of dystonia responsive to dopa
Authors:
L.R. Grinio, M.F. Mineeva, L.D. Karpova
Abstract:
Authors investigated the activity of enzyme Tyrosinhydroxilase (TH) in 15 children with clinic picture Segava disease (dystonia reacted dopha-DRD) before, during and after the treatment L-dopha (nacom). The activity of TH was determinate by the .new spectrophotometric method, which was worked by Mineeva, for the patients blood. This method permitted to reveal zero activity of TH before the treatment in the patients with DPD. The forms of TH were also were changed: TH1 and TH2 were absent, TH4 was expressed. During the treatment TH3 and TH4 were typical. Comparing these results studying of TH with the investigation in the patients with DNPD, it is possible to mark the great difference. In last group the activity of TH before the treatment was expressed and all 4 forms were presented. This fact may be useful as criterion for differentiation these two forms. Abolition of the treatment with nacom restored the clinic picture of immobility and changes of TH, this fact point out the disturbances in the dophamine metabolism in the patients with DPD as a reason of disease.
Pages: 64-68
References

  1. Segava M., Hosaka A., Miyagava F. et. al. Hereditary progressive dystonia with marked diurnal flustuation // Adv. Neurol. 1976. № 14. P. 215-233.
  2. Furakava Y. et al. Dopa responsive dystonia, clinical, genetic, biochemic // Neurol. Neusurg. Psych. 2009. № 50. P. 839-845.
  3. Niederwieser A., Blau N., et al. //GTP cyclohydrase 1 defiency, a new enzyme defect causing hyperphenylalanininemia with neopterin, biopterin, dofamine and serotonin deficiencies and muscular hypotonia //Eur.J., Pediatr. 1984. № 141. P. 208-214.
  4. Ludecke B., Knappskog P. et al. //Recessive inherited L-dopa-responsive parkinsonism in infancy caused by a point mutation in the tyrosinhydroxilase gene // Hum. Mol. Genet. 1996. № 7. P. 1023-1028.
  5. Clot F., Grabli D. et al. //Exhaustive analysis of BH4 and dopamine biosyntesis genes in patients with dopa-responsive dystonia // Brain. 2009. № 132. P. 1753-1763.
  6. Horvath G. Stockler-Ipsiroglu S. et al. //Autosomal recessive GTP cyclohydrolase 1 defiency without hyperphenylalaninnemia evidence of a phenotypic continuum between dominant and recessive forms // Mol. Genet. Metab. 2008. № 94. P. 127-131.
  7. Swoboda K., Furakawa Y. Tyrosine hydroxilase defiency // In Gene Reviews. Seatle. 2008. Feb. 08.
  8. Yeung W., Wong V., et al. Expanding phenotype and clinical analysis of tyrosine hydroxilase deficiency // J. Child Neurol. 2011. № 26. P. 179-187.
  9. Nagatsu T., Ichinose H. // Comparative studies on the structure of human tyrosin hydroxilase with those of the enzyme of various mammals // Comp. Bioh. Physiol. 1991. № 98. P. 203-210.
  10. Bodeau - Pean S., Ravassard P., et al. A human tyrosine hydroxilase isoform assosiated/. with progressive supranuclear palsy shows altered enzymatic activity // J. Biol. Chem. 1999. № 274. P. 157-163.
  11. Mineeva M.F. Tirozingidroksilaza lejkoczitov krovi // Byulleten' e'ksperimental'noj biologii i medicziny'. 1987. № 7. P. 99-101.
  12. Patent №2154277 RF klass GO1 N33/68 BI 1997 № 7 // M.F. Mineeva, L.D. Karpova.
  13. Grinio L.P. Sindrom dofaminovoj nedostatochnosti s polozhitel'noj reakcziej na L-dofu // Al'manax «Isczelenie». 2008. T. 3. S. 194-197.
  14. Grinio L. Clinical and, biochemical analysis of the variant dopa responsive dystonia in children // Europ. of Paediatric Neurology Mineenam. 1997. V. 1. № 2/3. H-24.
  15. Trender-Gerhard I., Sweeney M et al. Autosomal-domonant GTPCH 1-deficient DRD clinical characteristic and long-term outcome of 34 patients // J. Neurol. Neusurg. Psych. 2009. № 80. P. 839-845.
  16. Hagenah J., Saunders-Pullman R. et al. High mutation rate in dopa-responsive dystonia detection with comprehensive G T H I screening // Neurology. 2005. № 64. P. 908-911.
  17. Willensen M., Verbeek M., et al. Tyrosine hydroxilase deficiency: treatable disorder of brain catecholamine // Brain. 2010. № 133. P. 1810-1822.